Organic synthesis and improved biological properties of modified mRNA cap analogs

Current Organic Chemistry

Volumn 14, Issue 11, 2010, Pages 1083-1098

  Kore, Anilkumar R ^a   Charles, Irudaya ^a   Shanmugasundaram, Muthian ^a  

^a Life Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; BIOSYNTHESIS;

BIOLOGICAL APPLICATIONS; BIOLOGICAL PROPERTIES; CAP STRUCTURE; DINUCLEOSIDES; DINUCLEOTIDES; MESSENGER RNA; ORGANIC SYNTHESIS; RNA METABOLISMS; THERAPEUTIC APPLICATION; TRIPHOSPHATE;

NUCLEOTIDES;

EID: 77954899896     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527210791317076     Document Type: Article

References (80)

1. Niedzwiecka, A.; Marcotrigiano, J.; Stepinski, J.; Jankowska-Anyszka, M.; Wyslouch-Cieszynska, A.; Dadlez, M.; Gingras, A. C.; Mak, P.; Darzynkiewicz, E.; Sonenberg, N.; Burley, S. K.; Stolarski, R. Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J. Mol. Biol. 2002, 319 (3), 615-635.
2. Hu, G.; Gershon, P. D.; Hodel, A. E.; Quiocho, F. A. mRNA cap recognition: dominant role of enhanced stacking interactions between methylated bases and protein aromatic side chains. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (13), 7149-7154.
3. Mazza, C.; Segref, A.; Mattaj, I. W.; Cusack, S. Large-scale induced fit recognition of an m(7)GpppG cap analogue by the human nuclear cap binding complex. EMBO J. 2002, 21 (20), 5548-5557.
4. Kore, A. R.; Charles, I.; Shanmugasundaram, M.; Xiao, Z.; Conrad, R. C. Recent Developments in 5-Terminal Cap Analogs: Synthesis and Biological Ramifications. Mini-Rev. Org. Chem. 2008, 5, 179-192.
5. Hata, T.; Nakagawa, I.; Shimotohno, K.; Miura, K. The synthesis of, dinucleoside triphosphates. The confronted nucleotide structure found at the 5 -terminus of eukaryote messenger ribonucleic acid. Chem. Lett. 1976, 987-990.
6. Stepinski, J.; Waddell, C.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R. E. Synthesis and properties of mRNAs containing the novel anti-reverse cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA 2001, 7 (10), 1486-1495.
7. Life Technologies Corporation, 2130 Woodward Street, Austin, TX, 78744-1832, USA. Available from: http://www3.appliedbiosystems.com/AB_Home/index.htm
8. Mikkola, S.; Salomaeki, S.; Zhang, Z.; Maeki, E.; Loennberg, H. Preparation and properties of mRNA 5'-cap structure. Curr. Org. Chem. 2005, 9 (10), 999-1022.
9. Yamamoto, A.; Kormann, M.; Rosenecker, J.; Rudolph, C. Current prospects for mRNA gene delivery. Eur. J. Pharm. Biopharm. 2009, 71 (3), 484-489.
10. Nicolette, C. A.; Healey, D.; Tcherepanova, I.; Whelton, P.; Monesmith, T.; Coombs, L.; Finke, L. H.; Whiteside, T.; Miesowicz, F. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007, 25 Suppl 2, B47-60.
11. Grudzien-Nogalska, E.; Stepinski, J.; Jemielity, J.; Zuberek, J.; Stolarski, R.; Rhoads, R. E.; Darzynkiewicz, E. Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. Methods Enzymol. 2007, 431, 203-227.
12. Xiong, G.; Xiong, X.; Zhang, J. Relationship between mRNA structure and its stability. Xibao Shengwuxue Zazhi 2006, 28 (4), 513-517.
13. Kyte, J. A.; Gaudernack, G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol. Immunother. 2006, 55 (11), 1432-1442.
14. Nishikiori, M.; Ishikawa, M. The mechanisms of plant viral mRNA translation. Seikagaku 2005, 77 (1), 38-42.
15. Nakagawa, I.; Konya, S.; Ohtani, S.; Hata, T. A Capping Agent: P1-S-Phenyl P2-7-Methylguanosine-5 Pyrophosphorothioate. Synthesis 1980, 556.
16. Iwase, R.; Sekine, M.; Tokumoto, Y.; Ohshima, Y.; Hata, T. Synthesis of N2, N2, 7-trimethylguanosine cap derivatives. Nucleic Acids Res. 1989, 17 (22), 8979-8989.
17. Kamimura, T.; Osaki, Y.; Sekine, M.; Hata, T. An effective method for the synthesis of the cap structure of eukaryotic messenger ribonucleic acids. Tetrahedron Lett. 1984, 25 (25), 2683-2686.
18. 7G5 pppAUGACC. Bull. Chem. Soc. Jpn. 1985, 58, 850-860.
19. Fukuoka, K.; Suda, F.; Suzuki, R.; Takaku, H.; Ishikawa, M.; Hata, T. One-pot reaction for the synthesis of m7G5'pppG and m7G5'pppA by using an activatable bifunctional phosphorylating reagent. Tetrahedron Lett. 1994, 35 (7), 1063-1066.
20. Sawai, H.; Wakai, H.; Shimazu, M. Facile synthesis of cap portion of messenger RNA by Mn(II) ion-catalyzed pyrophosphate formation in aqueous solution Tetrahedron Lett. 1991, 32, 6905-6906.
21. Sawai, H.; Wakai, H.; Nakamura-Ozaki, A. Synthesis and reactions of nucleoside 5'-diphosphate imidazolide. A nonenzymatic capping agent for 5'-monophosphorylated oligoribonucleosides in aqueous solution. J. Org. Chem. 1999, 64, 5836-5840.
22. Jemielity, J.; Fowler, T.; Zuberek, J.; Stepinski, J.; Lewdorowicz, M.; Niedzwiecka, A.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R. E. Novel anti-reverse cap analogs with superior translational properties. RNA 2003, 9 (9), 1108-1122.
23. Peng, Z. H.; Sharma, V.; Singleton, S. F.; Gershon, P. D. Synthesis and application of a chain-terminating dinucleotide mRNA cap analog. Org. Lett. 2002, 4 (2), 161-164.
24. Sawai, H.; Shimazu, M.; Wakai, H.; Wakabayashi, H.; Shinozuka, K. Divalent metal ion-catalyzed pyrophosphate bond formation in aqueous solution.synthesis of nucleotides containing polyphospate. Nucleosides Nucleotides and Nucleic Acids, 1992, 11 (2-4), 773-785.
25. Kore, A. R.; Shanmugasundaram, M.; Vlassov, A. V. Synthesis and application of a new 2',3'-isopropylidene guanosine substituted cap analog. Bioorg. Med. Chem. Lett. 2008, 18 (17), 4828-4832.
26. Kore, A. R.; Shanmugasundaram, M.; Charles, I.; Vlassov, A. V.; Barta, T. J. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization. J. Am. Chem. Soc. 2009, 131 (18), 6364-6365.
27. Kore, A. R.; Shanmugasundaram, M. Design and Synthesis of New Cap Analogs Containing 2-OH Modifications on Both Guanosine and m7Guanosine Moieties. Lett. Org. Chem. 2009, 6 (2), 141-144.
28. Kore, A. R.; Shanmugasundaram, M. Synthesis and biological evaluation of trimethyl-substituted cap analogs. Bioorg. Med. Chem. Lett. 2008, 18 (3), 880-884.
29. Kore, A. R.; Charles, I.; Shanmugasundaram, M. Synthesis and Application of 2'-ara-Fluoroguanosine-substituted Cap Analog. Chem. Lett. 2009, 38 (7), 652-653.
30. Kore, A. R.; Shanmugasundaram, M.; Charles, I.; Cheng, A. M.; Barta, T. J. Synthesis and application of 2'-fluoro-substituted cap analogs. Bioorg. Med. Chem. Lett. 2007, 17 (19), 5295-5299.
31. Kowalska, J.; Lewdorowicz, M.; Zuberek, J.; Grudzien-Nogalska, E.; Bojarska, E.; Stepinski, J.; Rhoads, R. E.; Darzynkiewicz, E.; Davis, R. E.; Jemielity, J. Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS. RNA 2008, 14 (6), 1119-1131.
32. Kowalska, J.; Zuberek, J.; Darzynkiewicz, Z. M.; Lukaszewicz, M.; Darzynkiewicz, E.; Jemielity, J. The first examples of mRNA cap analogs bearing boranophosphate modification. Nucleic Acids Symp. Ser. (Oxf) 2008(52), 289-290.
33. Rydzik, A.; Zuberek, J.; Kowalska, J.; Lukaszewicz, M.; Darzynkiewicz, E.; Jemielity, J. Synthesis and biochemical studies of tetraphosphate 5' mRNA cap analogs bearing bisphosphonate modification. Nucleic Acids Symp. Ser. (Oxf) 2008, 52 (1), 287-288.
34. Poulin, F.; Sonenberg, N. Mechanism of translation initiation in eukaryotes. Translation Mechanisms 2003, 280-297.
35. Coller, J.; Parker, R. Eukaryotic mRNA decapping. Annu. Rev. Biochem. 2004, 73, 861-890.
36. Imataka, H. Eukaryotic translation and nuclear events. Tanpakushitsu Kakusan Koso. 2004, 49 (9), 1296-1301.
37. Merrick, W. C. Cap-dependent and cap-independent translation in eukaryotic systems. Gene 2004, 332, 1-11.
38. Meyer, S.; Temme, C.; Wahle, E. Messenger RNA Turnover in Eukaryotes: Pathways and Enzymes. Crit. Rev. Biochem. Mol. Biol. 2004, 39 (4), 197-216.
39. Fechter, P.; Brownlee, G. G. Recognition of mRNA cap structures by viral and cellular proteins. J. Gen. Virol. 2005, 86 (5), 1239-1249.
40. Polunovsky, V. A.; Bitterman, P. B. The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol. 2006, 3 (1), 10-17.
41. Rhoads, R. E.; Dinkova, T. D.; Korneeva, N. L. Mechanism and regulation of translation in C. elegans. WormBook 2006, 1-18.
42. Goodfellow, I. G.; Roberts, L. O. Eukaryotic initiation factor 4E. Int. J. Biochem. Cell Biol. 2008, 40(12), 2675-2680.
43. Grudzien, E.; Stepinski, J.; Jankowska-Anyszka, M.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R. E. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004, 10 (9), 1479-1487.
44. De Benedetti, A.; Harris, A. L. eIF4E expression in tumors: its possible role in progression of malignancies. Int. J. Biochem. Cell Biol. 1999, 31 (1), 59-72.
45. Miyagi, Y.; Sugiyama, A.; Asai, A.; Okazaki, T.; Kuchino, Y.; Kerr, S. J. Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of transformed cell lines. Cancer Lett. 1995, 91 (2), 247-252.
46. Rosenwald, I. B.; Lazaris-Karatzas, A.; Sonenberg, N.; Schmidt, E. V. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol. Cell. Biol. 1993, 13 (12), 7358-7363.
47. Kleiner, H. E.; Krishnan, P.; Tubbs, J.; Smith, M.; Meschonat, C.; Shi, R.; Lowery-Nordberg, M.; Adegboyega, P.; Unger, M.; Cardelli, J.; Chu, Q.; Mathis, J. M.; Clifford, J.; De Benedetti, A.; Li, B. D. Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. J. Exp. Clin. Cancer Res. 2009, 28, 5.
48. Graff, J. R.; Konicek, B. W.; Lynch, R. L.; Dumstorf, C. A.; Dowless, M. S.; McNulty, A. M.; Parsons, S. H.; Brail, L. H.; Colligan, B. M.; Koop, J. W.; Hurst, B. M.; Deddens, J. A.; Neubauer, B. L.; Stancato, L. F.; Carter, H. W.; Douglass, L. E.; Carter, J. H. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 2009, 69 (9), 3866-3873.
49. Fan, S.; Ramalingam, S. S.; Kauh, J.; Xu, Z.; Khuri, F. R.; Sun, S. Y. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol. Ther. 2009, 8 (15).
50. Borden, K. L. Tissue targeting in cancer: eIF4E's tale. Clin. Cancer Res. 2009, 15 (13), 4254-4255.
51. Assouline, S.; Culjkovic, B.; Cocolakis, E.; Rousseau, C.; Beslu, N.; Amri, A.; Caplan, S.; Leber, B.; Roy, D. C.; Miller, W. H., Jr.; Borden, K. L. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): aproof-of-principle clinical trial with ribavirin. Blood 2009, 114 (2), 257-260.
52. Konicek, B. W.; Dumstorf, C. A.; Graff, J. R. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 2008, 7 (16), 2466-2471.
53. Grudzien-Nogalska, E.; Jemielity, J.; Kowalska, J.; Darzynkiewicz, E.; Rhoads, R. E. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007, 13 (10), 1745-1755.
54. Kowalska, J.; Lewdorowicz, M.; Zuberek, J.; Bojarska, E.; Stepinski, J.; Stolarski, R.; Darzynkiewicz, E.; Jemielity, J. Assignment of the Absolute Configuration of P-Chiral 5'Mrna Cap Analogues Containing Phosphorothioate Moiety. Nucleosides Nucleotides Nucleic Acids 2007, 26 (10-12), 1301-1305.
55. Baraniak, J.; Frey, P. A. Effect of ion pairing on bond order and charge localization in alkyl phosphorothioates. J. Am. Chem. Soc. 2002, 110 (12), 4059-4060.
56. Saenger, W.; Eckstein, F. Stereochemistry of a substrate for pancreatic ribonuclease. Crystal and molecular structure of the triethylammonium salt of uridine 2,3 -O,O-cyclophosphorothioate. J. Am. Chem. Soc. 1970, 92, 4712-4718.
57. Frey, P. A.; Sammons, R. D. Bond order and charge localization in nucleoside phosphorothioate. Science 1985, 228, 541-545.
58. Jemielity, J.; Pietrowska-Borek, M.; Starzynska, E.; Kowalska, J.; Stolarski, R.; Guranowski, A.; Darzynkiewicz, E. Synthesis and enzymatic characterization of methylene analogs of adenosine 5'-tetraphosphate (P4A). Nucleosides Nucleotides Nucleic Acids 2005, 24 (5-7), 589-593.
59. Kalek, M.; Jemielity, J.; Grudzien, E.; Zuberek, J.; Bojarska, E.; Cohen, L. S.; Stepinski, J.; Stolarski, R.; Davis, R. E.; Rhoads, R. E.; Darzynkiewicz, E. Synthesis and biochemical properties of novel mRNA 5' cap analogs resistant to enzymatic hydrolysis. Nucleosides Nucleotides Nucleic Acids 2005, 24 (5-7), 615-621.
60. Grudzien, E.; Kalek, M.; Jemielity, J.; Darzynkiewicz, E.; Rhoads, R. E. Differential inhibition of mRNA degradation pathways by novel cap analogs. J. Biol. Chem. 2006, 281 (4), 1857.
61. Korner, C. G.; Wahle, E. Poly(A) tail shortening by a mammalian poly(A)-specific 3'-exoribonuclease. J. Biol. Chem. 1997, 272 (16), 10448-10456.
62. Hsu, C. L.; Stevens, A. Yeast cells lacking 5'->3' exoribonuclease 1 contain mRNA species that are poly(A) deficient and partially lack the 5' cap structure. Mol. Cell. Biol. 1993, 13 (8), 4826-4835.
63. Wang, Z.; Jiao, X.; Carr-Schmid, A.; Kiledjian, M. The hDcp2 protein is a mammalian mRNA decapping enzyme. Proc. Natl. Acad. Sci. USA 2002, 99 (20), 12663-12668.
64. Piccirillo, C.; Khanna, R.; Kiledjian, M. Functional characterization of the mammalian mRNA decapping enzyme hDcp2. RNA 2003, 9 (9), 1138-1147.
65. Steiger, M.; Carr-Schmid, A.; Schwartz, D. C.; Kiledjian, M.; Parker, R. Analysis of recombinant yeast decapping enzyme. RNA 2003, 9 (2), 231-238.
66. Chen, C. Y.; Gherzi, R.; Ong, S. E.; Chan, E. L.; Raijmakers, R.; Pruijn, G. J.; Stoecklin, G.; Moroni, C.; Mann, M.; Karin, M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001, 107 (4), 451-464.
67. Mukherjee, D.; Gao, M.; O'Connor, J. P.; Raijmakers, R.; Pruijn, G.; Lutz, C. S.; Wilusz, J. The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J. 2002, 21 (1-2), 165-174.
68. Wang, Z.; Kiledjian, M. Identification of an erythroid-enriched endoribonuclease activity involved in specific mRNA cleavage. EMBO J. 2000, 19 (2), 295-305.
69. Wang, Z.; Kiledjian, M. Functional link between the mammalian exosome and mRNA decapping. Cell 2001, 107 (6), 751-762.
70. Moss, B. The 5' terminal cap structures of eukaryotic and viral mRNAs. In Processing of RNA; Aspirion, D., Ed.; CRC Press, Inc.: Boca Raton, Florida, 1984, 119-132.
71. Shatkin, A. J. mRNA cap binding proteins: essential factors for initiating translation. Cell 1985, 40 (2), 223-224.
72. Varani, G. A cap for all occasions. Structure 1997, 5 (7), 855-858.
73. Van, T.; Ponsaerts, P.; Berneman, Z. N. mRNA-based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther. 2007, 9 (5), 423.
74. Mockey, M.; Bourseau, E.; Chandrashekhar, V.; Chaudhuri, A.; Lafosse, S.; Le Cam, E.; Quesniaux, V. F.; Ryffel, B.; Pichon, C.; Midoux, P. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007, 14 (9), 802-814.
75. Carralot, J. P.; Probst, J.; Hoerr, I.; Scheel, B.; Teufel, R.; Jung, G.; Rammensee, H. G.; Pascolo, S. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell. Mol. Life Sci. 2004, 61 (18), 2418-2424.
76. Hoerr, I.; Obst, R.; Rammensee, H. G.; Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 2000, 30 (1), 1-7.
77. Ishii, K. J.; Akira, S. TLR ignores methylated RNA? Immunity 2005, 23 (2), 111-113.
78. Kariko, K.; Ni, H.; Capodici, J.; Lamphier, M.; Weissman, D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 2004, 279 (13), 12542-12550.
79. Rozenski, J.; Crain, P. F.; McCloskey, J. A. The RNA Modification Database: 1999 update. Nucleic Acids Res. 1999, 27 (1), 196-197.
80. Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23 (2), 165-175.